<DOC>
	<DOC>NCT01691820</DOC>
	<brief_summary>The purpose of this study is to estimate the incidence of CMV secondary infections (re-infections/re-activations) and the incidence of CMV primary infections in adolescent females.</brief_summary>
	<brief_title>A Study in Adolescent Females to Explore Cytomegalovirus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>A female adolescent between, and including 10 and 17 years at the time of enrolment regardless of pregnancy status and contraception method used or not used. Subjects who the investigator believes that the subject and/or the subject's parent(s)/Legally Acceptable Representative(s) (LAR[s]) can and will comply with the requirements of the protocol. Written informed assent and/or consent obtained from the subject and/or the parent(s)/LAR(s) of the subject. Subject is likely to remain in the area and/or return for required study Site Visits and complete Sample Collection Visits. Child in care. Use or planned use of any investigational or nonregistered antiviral drug or vaccine during the study period. Known medical history of any recurrent clinical herpes episodes requiring episodic or chronic suppressive treatment with oral or parenteral antiviral treatment such as acyclovir, famciclovir, valacyclovir or any other antiherpes virus antiviral during the year preceding enrolment. Topical antiviral are allowed. Subjects with history of previous vaccination against CMV. Chronic administration of immunosuppressants or other immunemodifying drugs within 6 months prior to Visit 1 or planned administration during the study. Inhaled and topical steroids are allowed. Administration of immunoglobulins and/or any blood products within 3 months prior to Visit 1 or planned administration during the study. Any confirmed or suspected immunosuppressive or immunodeficient condition including HIVinfection, based on medical history and physical examination (no laboratory testing required). Any major congenital defects, serious chronic illness or organ transplantation.</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adolescent females</keyword>
	<keyword>Cytomegalovirus (CMV)</keyword>
</DOC>